AKUMS

Akums Drugs & Pharmaceuticals Share Price

 

 

Invest in Akums Drugs & Pharmaceuticals with 3.2X leverage

Invest with MTF
Akums Drugs & Pharmaceuticals live price: ₹493.35. It opened at ₹496 vs previous close ₹499; intraday high/low: ₹499/₹483. The 50 & 200 DMA stand at ₹471.52/₹490.15.

Akums Drugs & Pharmaceuticals Performance

  • Today's Low
  • ₹483
  • Today's High
  • ₹499
  • 52 Week Low
  • ₹405
  • 52 Week High
  • ₹623
  • Open Price₹496
  • Previous Close₹499
  • Volume120,418
  • 50 DMA₹471.52
  • 100 DMA₹466.33
  • 200 DMA₹490.15

Investment Returns

  • Over 1 Month + 2.14%
  • Over 3 Month + 10.28%
  • Over 6 Month + 10.57%
  • Over 1 Year + 9.91%

Smart Investing Starts Here Start SIP with Akums Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Akums Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 24.4
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 7,765
  • P/B Ratio
  • 2.4
  • Average True Range
  • 19.67
  • EPS
  • 20.62
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.81
  • RSI
  • 54.78
  • MFI
  • 37.68

Akums Drugs & Pharmaceuticals Financials

Akums Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹493.35
-5.7 (-1.14%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹481.52
  • 50 Day
  • ₹471.52
  • 100 Day
  • ₹466.33
  • 200 Day
  • ₹490.15

Resistance and Support

491.57 Pivot Speed
  • R3 516.68
  • R2 507.72
  • R1 500.53
  • S1 484.38
  • S2 475.42
  • S3 468.23

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Akums Drugs & Pharmaceuticals Ltd. is India’s leading contract manufacturing company, producing a wide range of pharmaceutical and nutraceutical products. It provides end-to-end solutions, including formulation development, manufacturing, and packaging for domestic and global clients.

Akums Drugs And Pharmaceuticals Ltd has an operating revenue of Rs. 4,256.70 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of 8% is okay, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 5% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 19% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 21 which is a POOR score indicating inconsistency in earnings, a RS Rating of 81 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 84 indicates it belongs to a poor industry group of Medical-Products and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Akums Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-13 Quarterly Results
2025-11-13 Quarterly Results
2025-08-08 Quarterly Results
2025-05-26 Audited Results
2025-02-06 Quarterly Results

Akums Drugs & Pharmaceuticals F&O

Akums Drugs & Pharmaceuticals Shareholding Pattern

75.26%
11.23%
0.65%
1.14%
5.51%
6.21%

Akums Drugs & Pharmaceuticals FAQs

Akums Drugs & Pharmaceuticals share price is ₹493 As on 06 April, 2026 | 23:47

The Market Cap of Akums Drugs & Pharmaceuticals is ₹7765 Cr As on 06 April, 2026 | 23:47

The P/E ratio of Akums Drugs & Pharmaceuticals is 24.4 As on 06 April, 2026 | 23:47

The PB ratio of Akums Drugs & Pharmaceuticals is 2.4 As on 06 April, 2026 | 23:47

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23